Floatz logo

Lanreotide

Non Functioning Entero-pancreatic Endocrine Tumour

Ipsenprotein_peptidePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Non Functioning Entero-pancreatic Endocrine Tumour cohort.

Asset / SponsorPhaseRating
Ribociclib
M.D. Anderson Cancer Center
Phase 2B
Spartalizumab
Novartis Pharmaceuticals
Phase 2CCC
Veliparib
Vanderbilt-Ingram Cancer Center
Phase 1CC
Capecitabine
Vanderbilt-Ingram Cancer Center
Phase 1CC
Bms-907351
National Cancer Institute (NCI)
Phase 3NR

Same molecule, other indications

Lanreotide is also rated in:

lymphoceleDormant
BB
Indicative ·
64 / 100
View asset →
malignant endocrine neoplasmDormant
BB
Indicative ·
64 / 100
View asset →
Rectal CarcinomaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →